Ovarian hyperstimulation syndrome (OHSS) remains the most serious iatrogenic complication of assisted reproductive technology (ART), despite dramatic progress in individualized protocols and embryo cryopreservation. Over the last decade, several evidence-based strategies—ranging from GnRH antagonist protocols with agonist triggers, to progesterone priming, dopaminergic agents, and elective embryo freezing—have substantially reduced OHSS incidence. Yet, the field has long lacked a unified protocol that safely applies to a wide spectrum of patients, including those with PCOS, low AMH, hyper-responders, endometriosis, and cost constraints. In 2025, accumulating data and real-world outcomes position IVF Lite as the ideal stimulation strategy for an OHSS-free clinic. This protocol combines mild ovarian stimulation with clomiphene citrate ± low-dose gonadotropins (60–150 IU), followed by blastocyst vitrification with or without trophectoderm biopsy for preimplantation genetic testing for aneuploidy (PGTA). Single euploid embryo transfer is performed in a later hormone replacement (HRT) or natural cycle, decoupling ovarian stimulation from embryo transfer and eliminating the risk of luteal OHSS. IVF Lite is adaptable, cost-conscious, and exceptionally safe—even in populations traditionally considered high risk. It represents the convergence of scientific minimalism, safety, and clinical effectiveness. This chapter synthesizes global experience and current best practices, compares competing stimulation strategies, and concludes with a compelling case for IVF Lite as the definitive protocol for OHSS prevention in modern ART programs.